UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| ||
(Address of principal |
| (Zip Code) |
executive offices) |
|
|
Registrant's telephone number, including area code: (
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02.Results of Operations and Financial Condition.
On May 4, 2023, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits
(d) Exhibits.
Exhibit No. | Description | |
104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 4, 2023 | NEXTCURE, INC. | |
|
|
|
| By: | /s/ Steven P. Cobourn |
| Name: | Steven P. Cobourn |
| Title: | Chief Financial Officer |
Exhibit 99.1
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
| – | Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs |
| – | First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) |
| – | Cash of approximately $145 million expected to fund operations into mid-2025 |
BELTSVILLE, Md. – May 4, 2023 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported first quarter 2023 financial results.
“Data updates on all three of our clinical programs are expected this year,” said Michael Richman, NextCure’s president and chief executive officer. “While advancing our pipeline, we have strived to remain capital efficient, and expect that we have financial runway of more than two years and the ability to achieve our meaningful near-term clinical milestones.”
Q1 2023 Business Highlights and Near-Term Milestones
NC410 (LAIR-2 fusion)
| ● | Continued enrollment in the Phase 1b/2 clinical trial evaluating NC410 in combination with pembrolizumab in patients with immune checkpoint refractory or naïve solid tumors. |
| ● | Phase 1b update is expected in the fourth quarter of 2023. |
NC762 (B7-H4 mAb)
| ● | Continued enrollment in the Phase 1b dose expansion study in patients with solid tumors and high expression of B7-H4. |
| ● | Phase 1b update is expected in the fourth quarter of 2023. |
NC525 (LAIR-1 mAb)
| ● | Dosed first patient in a Phase 1 monotherapy dose escalation and safety study evaluating NC525 in AML patients in February 2023. |
| ● | Initial Phase 1a data are expected in the fourth quarter of 2023. |
Financial Guidance
| ● | NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025. |
Financial Results for Quarter Ended March 31, 2023
| ● | Cash, cash equivalents, and marketable securities as of March 31, 2023, were $145.5 million as compared to $159.9 million as of December 31, 2022. The decrease of $14.4 million was primarily related to cash used to fund operations, and cash used to purchase fixed assets. |
| ● | Research and development expenses were $11.6 million for the quarter ended March 31, 2023, as compared to $15.0 million for the quarter ended March 31, 2022. The decrease of $3.4 million was primarily related to lower research and clinical costs. |
| ● | General and administrative expenses were $5.4 million for the quarter ended March 31, 2023, as compared to $5.7 million for the quarter ended March 31, 2022. The decrease of $0.3 million was primarily related to lower stock compensation costs and lower professional services costs. |
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines and other immune related-diseases to treat cancer. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.com
Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our immunomedicines. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “should,” “due,” “estimate,” “expect,” “intend,” “hope,” “may,” “objective,” “plan,” “predict,” “potential,”
“positioned,” “seek,” “target,” “towards,” “forward,” “later,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and no products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure’s FIND-IO platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in the Company’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Selected Financial Information | | | | | | |
| | | | | | |
Selected Statement of Operations Items: | | Three Months Ended | ||||
| | March 31, | ||||
(in thousands, except share and per share amounts) | | 2023 |
| 2022 | ||
Operating expenses: | | | | | | |
Research and development | | $ | 11,647 | | $ | 15,024 |
General and administrative | | | 5,424 | | | 5,747 |
Loss from operations | |
| (17,071) | |
| (20,771) |
Other income, net | |
| 975 | |
| 169 |
Net loss | | $ | (16,096) | | $ | (20,602) |
Net loss per common share - basic and diluted | | $ | (0.58) | | $ | (0.74) |
Weighted-average shares outstanding - basic and diluted | | | 27,774,536 | | | 27,708,768 |
| | | | | | |
Selected Balance Sheet Items: | | | | | | |
| | | March 31, | | | December 31, |
(in thousands) | | | 2023 | |
| 2022 |
Cash, cash equivalents, and marketable securities | | $ | 145,493 | | $ | 159,911 |
Total assets | | $ | 167,791 | | $ | 184,161 |
Accounts payable and accrued liabilities | | $ | 6,266 | | $ | 9,127 |
Total stockholders' equity | | $ | 154,203 | | $ | 167,530 |
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com